08172017Headline:

Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy

Jun 11, 2017 - (Newswire)

- New results from the phase 3b DUAL VII clinical trial showed that Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight in adults with type 2 diabetes compared to treatment with basal-bolus therapy (insulin glargine U100 and insulin aspart).1 Results from the trial were presented today at the American Diabetes Association's 77th Scientific Sessions (ADA) in San Diego, CA, U.S.

In DUAL VII, Xultophy® 100/3.6 demonstrated non-inferiority in lowering A1C when compared to insulin glargine U100 in combination with insulin aspart.1 Those treated with Xultophy® 100/3.6 versus basal-bolus therapy also:1

  • reached similar glycemic targets (66.0% vs 67.0% for A1C

Original Source: https://www.newswire.com/news/xultophy-100-3-6-demonstrated-similar-a1c-reductions-with-significantly-lower

What Next?

Related Articles

Leave a Reply

Submit Comment